



Transgene Announces Participation at Upcoming Investor Events

Strasbourg, France, May 18, 2015 – Transgene today announced that management will participate in several upcoming investor events as outlined below.

BioEquity Europe: Transgene will give a corporate presentation on May 20 at 9:40 AM CET. The conference is being held in Vienna, Austria, May 19-20.

Gilbert Dupont Healthcare Forum: Transgene will meet with institutional investors in Paris, France on May 21.

'Spring' European Midcap Event: Transgene will meet with institutional investors on July 1-2 in Paris.

About Transgene

Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company's two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S. Additional information about Transgene is available at www.transgene.fr.

Contacts:

Transgene

Elisabetta Castelli, Director IR
+33 (0)3 88 27 91 21

Laurie Doyle, Director IR US
& Corporate Communications
+1 (339) 832 0752

investorrelations@transgene.fr

MC Services

Raimund Gabriel
+49 89 210 228 30
raimund.gabriel@mc-services.eu

Shaun Brown
+44 207 148 5998
shaun.brown@mc-services.eu